Patents by Inventor Kathrin U. Jansen

Kathrin U. Jansen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7976848
    Abstract: Synthetic DNA molecules encoding the HPV58 L1 protein are provided. Specifically, the present invention provides polynucleotides encoding HPV58 L1 protein, wherein said polynucleotides are codon-optimized for high level expression in a yeast cell. The synthetic molecules may be used to produce HPV58 virus-like particles (VLPs), and to produce vaccines and pharmaceutical compositions comprising the HPV58 VLPs. The vaccines of the present invention provide effective immunoprophylaxis against papillomavirus infection through neutralizing antibody and cell-mediated immunity and are also useful for treatment of existing HPV infections.
    Type: Grant
    Filed: January 26, 2009
    Date of Patent: July 12, 2011
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Janine T. Bryan, Michelle K. Brownlow, Loren D. Schultz, Xin-Min Wang, Kathrin U. Jansen
  • Publication number: 20100272749
    Abstract: Synthetic DNA molecules encoding the HPV58 L1 protein are provided. Specifically, the present invention provides polynucleotides encoding HPV58 L1 protein, wherein said polynucleotides are codon-optimized for high level expression in a yeast cell. The synthetic molecules may be used to produce HPV58 virus-like particles (VLPs), and to produce vaccines and pharmaceutical compositions comprising the HPV58 VLPs. The vaccines of the present invention provide effective immunoprophylaxis against papillomavirus infection through neutralizing antibody and cell-mediated immunity and are also useful for treatment of existing HPV infections.
    Type: Application
    Filed: January 26, 2009
    Publication date: October 28, 2010
    Inventors: Janine T. Bryan, Michelle K. Brownlow, Loren D. Schultz, Xin-Min Wang, Kathrin U. Jansen
  • Publication number: 20100203496
    Abstract: The present invention relates a fluorescent multiplex PCR assay for detecting the presence of a nucleic acid sequence of an HPV type in a sample using multiple fluorophores to simultaneously detect a plurality of HPV genes of the same HPV type, wherein the HPV type is selected from the group consisting of: HPV31, HPV45, HPV52, and HPV58. The present invention also relates to oligonucleotide primers and probes specific to said HPV types for use in the methods of the present invention.
    Type: Application
    Filed: April 24, 2006
    Publication date: August 12, 2010
    Inventors: Frank J. Taddeo, Deemarie Skulsky, Xin-Min Wang, Kathrin U. Jansen
  • Patent number: 7744892
    Abstract: Synthetic DNA molecules encoding the HPV 52 L1 protein are provided. Specifically, the present invention provides polynucleotides encoding HPV 52 L1 protein, wherein said polynucleotides are codon-optimized for high level expression in a yeast cell. In alternative embodiments of the invention, the nucleotide sequence of the synthetic molecule is altered to eliminate transcription termination signals that are recognized by yeast. The synthetic molecules may be used to produce HPV 52 virus-like particles (VLPs), and to produce vaccines and pharmaceutical compositions comprising the HPV 52 VLPs. The vaccines of the present invention provide effective immunoprophylaxis against papillomavirus infection through neutralizing antibody and cell-mediated immunity and may also be useful for treatment of existing HPV infections.
    Type: Grant
    Filed: October 14, 2009
    Date of Patent: June 29, 2010
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Janine T. Bryan, Michelle K. Brownlow, Loren D. Schultz, Kathrin U. Jansen
  • Patent number: 7700103
    Abstract: Synthetic DNA molecules encoding the HPV 52 L1 protein are provided. Specifically, the present invention provides polynucleotides encoding HPV 52 L1 protein, wherein said polynucleotides are codon-optimized for high level expression in a yeast cell. In alternative embodiments of the invention, the nucleotide sequence of the synthetic molecule is altered to eliminate transcription termination signals that are recognized by yeast. The synthetic molecules may be used to produce HPV 52 virus-like particles (VLPs), and to produce vaccines and pharmaceutical compositions comprising the HPV 52 VLPs. The vaccines of the present invention provide effective immunoprophylaxis against papillomavirus infection through neutralizing antibody and cell-mediated immunity and may also be useful for treatment of existing HPV infections.
    Type: Grant
    Filed: March 18, 2005
    Date of Patent: April 20, 2010
    Assignee: Merck & Co., Inc.
    Inventors: Janine T. Bryan, Michelle K. Brownlow, Loren D. Schultz, Kathrin U. Jansen
  • Publication number: 20100035818
    Abstract: Synthetic DNA molecules encoding the HPV 52 L1 protein are provided. Specifically, the present invention provides polynucleotides encoding HPV 52 L1 protein, wherein said polynucleotides are codon-optimized for high level expression in a yeast cell. In alternative embodiments of the invention, the nucleotide sequence of the synthetic molecule is altered to eliminate transcription termination signals that are recognized by yeast. The synthetic molecules may be used to produce HPV 52 virus-like particles (VLPs), and to produce vaccines and pharmaceutical compositions comprising the HPV 52 VLPs. The vaccines of the present invention provide effective immunoprophylaxis against papillomavirus infection through neutralizing antibody and cell-mediated immunity and may also be useful for treatment of existing HPV infections.
    Type: Application
    Filed: October 14, 2009
    Publication date: February 11, 2010
    Inventors: Janine T. Bryan, Michelle K. Brownlow, Loren D. Schultz, Kathrin U. Jansen
  • Publication number: 20100003665
    Abstract: The present invention relates a fluorescent multiplex PCR assay for detecting the presence of an HPV type in a sample using multiple fluorophores to simultaneously detect a plurality of HPV genes of the same HPV type, wherein the HPV type is selected from the group consisting of: HPV33, HPV35, HPV39, HPV51, HPV56, and HPV59. The present invention also relates to oligonucleotide primers and probes specific to said HPV types for use in the methods of the present invention.
    Type: Application
    Filed: April 24, 2006
    Publication date: January 7, 2010
    Inventors: Frank J. Taddeo, DeeMarie Skulsky, Xin-Min Wang, Kathrin U. Jansen
  • Patent number: 7498036
    Abstract: Synthetic DNA molecules encoding the HPV58 L1 protein are provided. Specifically, the present invention provides polynucleotides encoding HPV58 L1 protein, wherein said polynucleotides are codon-optimized for high level expression in a yeast cell. The synthetic molecules may be used to produce HPV58 virus-like particles (VLPs), and to produce vaccines and pharmaceutical compositions comprising the HPV58 VLPs. The vaccines of the present invention provide effective imnunoprophylaxis against papillomavirus infection through neutralizing antibody and cell-mediated immunity and are also useful for treatment of existing HPV infections.
    Type: Grant
    Filed: November 10, 2004
    Date of Patent: March 3, 2009
    Assignee: Merck & Co., Inc.
    Inventors: Janine T. Bryan, Michelle K. Brownlow, Loren D. Schultz, Xin-Min Wang, Kathrin U. Jansen
  • Patent number: 7482428
    Abstract: Synthetic DNA molecules encoding the HPV31 L1 protein are provided. Specifically, the present invention provides polynucleotides encoding HPV31 L1 protein, wherein said polynucleotides are free from internal transcription termination signals that are recognized by yeast. Also provided are synthetic polynucleotides encoding HPV31 L1 wherein the polynucleotides have been codon-optimized for high level expression in a yeast cell. The synthetic molecules may be used to produce HPV31 virus-like particles (VLPs), and to produce vaccines and pharmaceutical compositions comprising the HPV31 VLPs. The vaccines of the present invention provide effective immunoprophylaxis against papillomavirus infection through neutralizing antibody and cell-mediated immunity.
    Type: Grant
    Filed: July 19, 2007
    Date of Patent: January 27, 2009
    Assignee: Merck & Co., Ltd.
    Inventors: Kathrin U. Jansen, Loren D. Schultz, Michael P. Neeper, Henry Z. Markus
  • Patent number: 7482015
    Abstract: Synthetic DNA molecules encoding the HPV45 L1 protein are provided. Specifically, the present invention provides polynucleotides encoding HPV45 L1 protein, wherein said polynucleotides have been codon-optimized for high level expression in a yeast cell. The synthetic molecules may be used to produce HPV45 virus-like particles (VLPs), and to produce vaccines and pharmaceutical compositions comprising the HPV45 VLPs. The vaccines of the present invention provide effective immunoprophylaxis against papillomavirus infection through neutralizing antibody and cell-mediated immunity.
    Type: Grant
    Filed: May 23, 2007
    Date of Patent: January 27, 2009
    Assignee: Merck & Co., Inc.
    Inventors: Janine T. Bryan, Michelle K. Brownlow, Loren D. Schultz, Kathrin U. Jansen
  • Publication number: 20080226660
    Abstract: Synthetic DNA molecules encoding the HPV 52 L1 protein are provided. Specifically, the present invention provides polynucleotides encoding HPV 52 L1 protein, wherein said polynucleotides are codon-optimized for high level expression in a yeast cell. In alternative embodiments of the invention, the nucleotide sequence of the synthetic molecule is altered to eliminate transcription termination signals that are recognized by yeast. The synthetic molecules may be used to produce HPV 52 virus-like particles (VLPs), and to produce vaccines and pharmaceutical compositions comprising the HPV 52 VLPs. The vaccines of the present invention provide effective immunoprophylaxis against papillomavirus infection through neutralizing antibody and cell-mediated immunity and may also be useful for treatment of existing HPV infections.
    Type: Application
    Filed: March 18, 2005
    Publication date: September 18, 2008
    Inventors: Janine T. Bryan, Michelle K. Brownlow, Loren D. Schultz, Kathrin U. Jansen
  • Publication number: 20080166371
    Abstract: Synthetic DNA molecules encoding the HPV31 L1 protein are provided. Specifically, the present invention provides polynucleotides encoding HPV31 L1 protein, wherein said polynucleotides are free from internal transcription termination signals that are recognized by yeast. Also provided are synthetic polynucleotides encoding HPV31 L1 wherein the polynucleotides have been codon-optimized for high level expression in a yeast cell. The synthetic molecules may be used to produce HPV31 virus-like particles (VLPs), and to produce vaccines and pharmaceutical compositions comprising the HPV31 VLPs. The vaccines of the present invention provide effective immunoprophylaxis against papillomavirus infection through neutralizing antibody and cell-mediated immunity.
    Type: Application
    Filed: July 19, 2007
    Publication date: July 10, 2008
    Inventors: Kathrin U. Jansen, Loren D. Schultz, Michael P. Neeper, Henry Z. Markus
  • Publication number: 20080138361
    Abstract: Synthetic DNA molecules encoding the HPV45 L1 protein are provided. Specifically, the present invention provides polynucleotides encoding HPV45 L1 protein, wherein said polynucleotides have been codon-optimized for high level expression in a yeast cell. The synthetic molecules may be used to produce HPV45 virus-like particles (VLPs), and to produce vaccines and pharmaceutical compositions comprising the HPV45 VLPs. The vaccines of the present invention provide effective immunoprophylaxis against papillomavirus infection through neutralizing antibody and cell-mediated immunity.
    Type: Application
    Filed: May 23, 2007
    Publication date: June 12, 2008
    Inventors: Janine T. Bryan, Michelle K. Brownlow, Loren D. Schultz, Kathrin U. Jansen
  • Patent number: 7276243
    Abstract: Synthetic DNA molecules encoding the HPV31 L1 protein are provided. Specifically, the present invention provides polynucleotides encoding HPV31 L1 protein, wherein said polynucleotides are free from internal transcription termination signals that are recognized by yeast. Also provided are synthetic polynucleotides encoding HPV31 L1 wherein the polynucleotides have been codon-optimized for high level expression in a yeast cell. The synthetic molecules may be used to produce HPV31 virus-like particles (VLPs), and to produce vaccines and pharmaceutical compositions comprising the HPV31 VLPs.
    Type: Grant
    Filed: March 19, 2004
    Date of Patent: October 2, 2007
    Assignee: Merck & Co., Inc.
    Inventors: Kathrin U. Jansen, Loren D. Schultz, Michael P. Neeper, Henry Z. Markus
  • Patent number: 7250170
    Abstract: Synthetic DNA molecules encoding the HPV45 L1 protein are provided. Specifically, the present invention provides polynucleotides encoding HPV45 L1 protein, wherein said polynucleotides have been codon-optimized for high level expression in a yeast cell. The synthetic molecules may be used to produce HPV45 virus-like particles (VLPs), and to produce vaccines and pharmaceutical compositions comprising the HPV45 VLPs. The vaccines of the present invention provide effective immunoprophylaxis against papillomavirus infection through neutralizing antibody and cell-mediated immunity.
    Type: Grant
    Filed: September 24, 2004
    Date of Patent: July 31, 2007
    Assignee: Merck & Co., Inc.
    Inventors: Janine T. Bryan, Michelle K. Brownlow, Loren D. Schultz, Kathrin U. Jansen
  • Patent number: 7211569
    Abstract: Synthetic DNA molecules encoding papillomavirus proteins are provided. The codons of the synthetic molecules are codons preferred by the projected host cell. The synthetic molecules may be used as a polynucleotide vaccine which provides effective immunoprophylaxis against papillomavirus infection through stimulation of neutralizing antibody and cell-mediated immunity.
    Type: Grant
    Filed: December 4, 2003
    Date of Patent: May 1, 2007
    Assignee: Merck & Co., Inc.
    Inventors: Michael P Neeper, William L. McClements, Kathrin U. Jansen, Loren D. Schultz, Ling Chen, Xin-Min Wang
  • Patent number: 7157443
    Abstract: A high molecular weight polysaccharide intracellular adhesin (SAE) antigen having the general structure of poly-1,6,?-2-amidoglucopyranoside, which is variable substituted with N-acetyl and O-succinyl substituents is described. Also, a method is given for isolating this antigen from Staphylococcus aureus. The SAE can be used in a vaccine, either alone, conjugated to an immunogenic protein, and/or with an immunogenic adjuvant.
    Type: Grant
    Filed: December 6, 2002
    Date of Patent: January 2, 2007
    Assignee: Merck & Co., Inc.
    Inventors: Joseph G. Joyce, James C. Cook, III, Chitrananda Abeygunawardana, Karen M. Grimm, Craig T. Przysiecki, Robert W. Hepler, Charlotte C. Ip, Keith Roper, Qiuwei Xu, Kathrin U. Jansen, Paul M. Keller, Leslie D. Cope
  • Patent number: 7033797
    Abstract: The invention is a series of synthetic virus-like particles comprising a heterologous conformational epitope useful in the characterization of human papillomavirus infection, and useful to vaccinate individual for protection against HPV 6 and HPV 11 infections, and assays employing the synthetic virus-like particles.
    Type: Grant
    Filed: December 16, 2003
    Date of Patent: April 25, 2006
    Assignee: Merck & Co., Inc.
    Inventors: Kathrin U. Jansen, Jessica C. Ling, Steven W. Ludmerer, William L. McClements, Xin-Min Wang
  • Patent number: 7001995
    Abstract: Synthetic DNA molecules encoding papillomavirus proteins are provided. The codons of the synthetic molecules are codons preferred by the projected host cell. The synthetic molecules may be used as a polynucleotide vaccine which provides effective immunoprophylaxis against papillomavirus infection through stimulation of neutralizing antibody and cell-mediated immunity.
    Type: Grant
    Filed: August 21, 2000
    Date of Patent: February 21, 2006
    Assignee: Merck & Co., Inc.
    Inventors: Michael P Neeper, William L. McClements, Kathrin U. Jansen, Loren D. Schultz, Ling Chen, Xin-Min Wang
  • Patent number: 6991795
    Abstract: Human Papillomavirus virus like particles (VLPs) have been constructed so that they contain a modified L2 protein. The L2 protein has been minimized and is fused to a second protein or peptide. The fused protein is incorporated into the VLP and the VLP can deliver the protein to a cell. The modified VLPs can be used to increase the breadth of immune response in vaccine preparations or to deliver other proteins of interest.
    Type: Grant
    Filed: August 10, 1999
    Date of Patent: January 31, 2006
    Assignee: Merck & Co., Inc.
    Inventors: Robert S. Lowe, Kathrin U. Jansen, Joseph G. Joyce, William L. McClements, James C. Cook, III, Jessica Ching-Yee Ling, Michael P. Neeper